Eli Lilly and Company has launched a new, easier-to-use Forteo delivery pen for osteoporosis treatment in India.
Forteo delivery pen, which contains recombinant teriparatide prefilled injections, is the advanced device has been specifically designed for osteoporosis patients.
Forteo delivery pen would enable easy administration of teriparatide treatment on a day-to-day basis.
Forteo is a prescription therapy, available on the advice of a registered medical practitioner only.
Patients and healthcare professionals have directly contributed in the design process of this new Pen by providing feedback on the existing device on the market.
Compared to the present Forteo delivery device, the new design Forteo Pen includes a larger and wider body and takes fewer (2 as compared to the previous 8) steps to complete the injection process.
The novel design also ensures that priming the injection is no longer required making injection process, a much simpler one. Added convenience of color coded parts in the new device enhances patient comprehension and compliance, the company said in a press release.
“We hope that this simpler design will help patients adhere to their Forteo treatment plan so they can receive the full benefits of their medication,” said Sandeep Gupta, CMD Eli Lilly India.
Forteo is used in both men and postmenopausal women with osteoporosis at high risk for having broken bones (fractures) in both men and women with osteoporosis due to use of glucocorticoids, such as prednisone, for several months, at high risk for having broken bones.
The Forteo delivery device has enough medicine for 28 days. It is set to give a 20-microgram dose of medicine each day.
This can result in taking the wrong dose of Forteo. If you take more FORTEO than prescribed, call your healthcare provider. If you take too much FORTEO, you may have nausea, vomiting, weakness, or dizziness.
This is the second state-of-the-art device that Lilly has launched in India in the last couple of weeks after the launch of its new Humalog KwikPen in the diabetes segment.
Eli Lilly and Company launched its latest insulin delivery device, Humalog KwikPen, a pre-filled pen that contains Humalog (Insulin Lispro, rDNA origin) brand of insulins.
Headquartered in Indianapolis, Ind., Eli Lilly is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.